{
    "clinical_study": {
        "@rank": "43569", 
        "arm_group": [
            {
                "arm_group_label": "Phase Ib: Buparlisib + docetaxel", 
                "arm_group_type": "Experimental", 
                "description": "Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label."
            }, 
            {
                "arm_group_label": "Phase II: Buparlisib + docetaxel", 
                "arm_group_type": "Experimental", 
                "description": "Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label."
            }, 
            {
                "arm_group_label": "Phase II: Placebo + docetaxel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label Phase Ib dose escalation part followed by a randomized\n      double-blinded placebo controlled Phase II part."
        }, 
        "brief_title": "Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The Phase Ib part will determine the Maximum Tolerated Dose (MTD)/Recommended Phase II Dose\n      (RP2D) of buparlisib in combination with docetaxel.\n\n      Subsequently the MTD/RP2D will be investigated in a Phase II randomized trial in patients\n      with advanced or metastatic squamous NSCLC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is an adult  \u2265 18 years old at the time of informed consent\n\n          -  Patient has histologically and/or cytologically confirmed diagnosis of squamous\n             NSCLC. Diagnosis of mixed squamous and non-squamous or adenosquamous NSCLC will be\n             acceptable for enrollment.\n\n          -  Patient has received one prior approved regimen of platinum-based chemotherapy\n             (excluding a docetaxel-containing regimen) for advanced or metastatic (Stage IIIb or\n             Stage IV) squamous NSCLC, followed by disease progression.  A drug provided as\n             maintenance therapy following cytotoxic chemotherapy will be considered to be part of\n             that regimen.\n\n        Note: Patients who received paclitaxel therapy are eligible for this trial. \u2022Patient has\n        adequate tumor tissue (either archival or new tumor biopsy) for the analysis of\n        PI3K-related biomarkers.\n\n        Enrollment in the Phase II part of the study is contingent on the central laboratory\n        confirming receipt of an adequate amount of tissue including sufficient DNA for analysis.\n\n        \u2022Patient has measurable or non-measurable disease according to RECIST version 1.1\n        criteria.\n\n        Phase II only: Patient must have at least one measurable lesion as per RECIST criteria.\n\n          -  Patient has an ECOG performance status \u2264 1\n\n          -  Patient has adequate bone marrow and organ function\n\n        Exclusion Criteria:\n\n          -  Patient has received previous treatment with a PI3K or AKT inhibitor\n\n          -  Patient has symptomatic Central Nervous System (CNS) metastases Patients with\n             asymptomatic CNS metastases may participate in this trial. The patient must have\n             completed prior local treatment, if any, for CNS metastases \u2265 28 days prior to the\n             start of study treatment (including radiotherapy and/or surgery, or \u2265 14 days for\n             stereotactic radiosurgery).\n\n          -  Patient has a score \u2265 12 on the PHQ-9 questionnaire.\n\n          -  Patient selects a response of \"1, 2 or 3\" to question number 9 on the PHQ-9\n             questionnaire regarding potential for suicidal thoughts or ideation (independent of\n             the total score of the PHQ-9).\n\n          -  Patient has a GAD-7 mood scale score \u2265 15.\n\n          -  Patient has a medically documented history of or active major depressive episode,\n             bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history\n             of suicidal attempt or ideation, or homicidal ideation or patients with active severe\n             personality disorders.\n\n          -  Patient has \u2265 CTCAE grade 3 anxiety"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "222", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911325", 
            "org_study_id": "CBKM120D2205", 
            "secondary_id": "2013-000833-11"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Phase Ib: Buparlisib + docetaxel", 
                    "Phase II: Buparlisib + docetaxel"
                ], 
                "intervention_name": "Buparlisib", 
                "intervention_type": "Drug", 
                "other_name": "BKM120"
            }, 
            {
                "arm_group_label": "Phase II: Placebo + docetaxel", 
                "intervention_name": "Buparlisib matching placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Phase Ib: Buparlisib + docetaxel", 
                    "Phase II: Buparlisib + docetaxel", 
                    "Phase II: Placebo + docetaxel"
                ], 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Squamous non-small cell lung cancer", 
            "NSCLC", 
            "Docetaxel", 
            "Buparlisib", 
            "BKM120", 
            "Metastatic", 
            "Stage IIIb", 
            "Stage IV", 
            "PI3K inhibitor"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": [
            {
                "contact": {
                    "email": "thesington@hogonc.com", 
                    "last_name": "Tia Hesington", 
                    "phone": "479-936-9900"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "Highlands Oncology Group SC-1"
                }, 
                "investigator": {
                    "last_name": "Eric S. Schaefer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jennifer.hege@usoncology.com", 
                    "last_name": "Jennifer Hege", 
                    "phone": "303-388-4876"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenwood Village", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Rocky Mountain Cancer Centers Rocky Mountain Cancer Centers"
                }, 
                "investigator": {
                    "last_name": "Robert M. Jotte", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ree28@georgetown.edu", 
                    "last_name": "Rebecca Eberle", 
                    "phone": "202-687-5791"
                }, 
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown University/Lombardi Cancer Center Georgetown Univ. Medical Ctr."
                }, 
                "investigator": {
                    "last_name": "Giuseppe Giaccone", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jeff.jorski@moffitt.org", 
                    "last_name": "Jeff L. Jorski", 
                    "phone": "813-745-6895"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt"
                }, 
                "investigator": {
                    "last_name": "Jhanelle Gray", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sonia.martinath@reliantmedicalgroup.org", 
                    "last_name": "Sonia Martinath"
                }, 
                "facility": {
                    "address": {
                        "city": "Worchester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01608"
                    }, 
                    "name": "Reliant Medical Group Reliant Medical Group"
                }, 
                "investigator": {
                    "last_name": "Saleem Khanani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sgajavel@montefiore.org", 
                    "last_name": "Srkantha Gajavelli", 
                    "phone": "718-405-8539"
                }, 
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10461"
                    }, 
                    "name": "Montefiore Medical Center SC BKM120 D2204 / D2205"
                }, 
                "investigator": {
                    "last_name": "Bilal Piperdi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "phone": "716-845-4886"
                }, 
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute Rosewell"
                }, 
                "investigator": {
                    "last_name": "Grace Dy", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "denise.hill@usoncology.com", 
                    "last_name": "Denise Hill", 
                    "phone": "360-449-6522"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Northwest Cancer Specialists Compass Oncology -BKM"
                }, 
                "investigator": {
                    "last_name": "David A. Smith", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hendrij@musc.edu", 
                    "last_name": "Kate Hendricks", 
                    "phone": "843-792-1463"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina MUSC"
                }, 
                "investigator": {
                    "last_name": "Keisuke Shirai", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "llynch@jonescancerclinic.com", 
                    "last_name": "Lori Lynch", 
                    "phone": "+1 901 685 5969 ext 328"
                }, 
                "facility": {
                    "address": {
                        "city": "Germantown", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38138"
                    }, 
                    "name": "The Jones Clinic SC"
                }, 
                "investigator": {
                    "last_name": "C. Michael Jones", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ecox@biomed-research.com", 
                    "last_name": "Erica Cox", 
                    "phone": "865-934-2675"
                }, 
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37909"
                    }, 
                    "name": "Tennessee Cancer Specialists Center for Biomedical Research"
                }, 
                "investigator": {
                    "last_name": "Russell F DeVore", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Emily.angarole@scresearch.net", 
                    "last_name": "Emily Angarole", 
                    "phone": "615-524-4086"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute BKM120D2204/BKM120D2205"
                }, 
                "investigator": {
                    "last_name": "David R. Spigel", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "US Oncology Central Monitoring"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "Ron.schoenfeldt@McKesson.com", 
                    "last_name": "Ron Schoenfeldt", 
                    "phone": "817-850-2000"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "Texas Oncology, P.A."
                }, 
                "investigator": {
                    "last_name": "Stephen L. Richey", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "susan.cooper@uth.tmc.edu", 
                    "last_name": "Susan Cooper", 
                    "phone": "832-325-7308"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas Health Science Center Univ.TX Memorial Herman Cancer"
                }, 
                "investigator": {
                    "last_name": "Shan Guo", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ngarcia@stexresearch.com", 
                    "last_name": "Noe Garcia", 
                    "phone": "956-753-7839"
                }, 
                "facility": {
                    "address": {
                        "city": "Laredo", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78041"
                    }, 
                    "name": "Institute of Oncology Hematology"
                }, 
                "investigator": {
                    "last_name": "Eduardo Miranda", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Jonese5@uthscsa.edu", 
                    "last_name": "Ellen Jones", 
                    "phone": "210-450-1789"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Cancer Therapy & Research Center / UT Health Science Center BKM120D2204"
                }, 
                "investigator": {
                    "last_name": "Athanassios Ethan Argiris", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gabrielle.whalen@usocology.com", 
                    "last_name": "Gabrielle Whalen", 
                    "phone": "757-213-5658"
                }, 
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "Virginia Oncology Associates BKM120D2205/BKM120D2204"
                }, 
                "investigator": {
                    "last_name": "Paul Conkling", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleroi", 
                        "country": "Belgium", 
                        "zip": "6000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mons", 
                        "country": "Belgium", 
                        "zip": "7000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bogot\u00e1", 
                        "country": "Colombia"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monteria", 
                        "country": "Colombia"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Herblain cedex", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyor", 
                        "country": "Hungary", 
                        "zip": "9023"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nyiregyhaza", 
                        "country": "Hungary", 
                        "zip": "4400"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Veszpr\u00e9m", 
                        "country": "Hungary", 
                        "zip": "8200"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zalaegerszeg-P\u00f3zva", 
                        "country": "Hungary", 
                        "zip": "8900"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cremona", 
                        "country": "Italy", 
                        "state": "CR", 
                        "zip": "26100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "state": "GE", 
                        "zip": "16132"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy", 
                        "state": "MB", 
                        "zip": "20900"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20141"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Terni", 
                        "country": "Italy", 
                        "state": "TN", 
                        "zip": "05100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy", 
                        "state": "UD", 
                        "zip": "33100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "135-710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "738-736"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation", 
                        "zip": "454087"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "115478"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sankt-Peterburg", 
                        "country": "Russian Federation", 
                        "zip": "197022"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia", 
                        "zip": "813 69"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "state": "Andalucia", 
                        "zip": "41013"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08036"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "171 76"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "34303"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izmir", 
                        "country": "Turkey"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izmir", 
                        "country": "Turkey", 
                        "zip": "35340"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izmir", 
                        "country": "Turkey", 
                        "zip": "35040"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom", 
                        "zip": "CB2 2QQ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE1 9RT"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Colombia", 
                "France", 
                "Germany", 
                "Hungary", 
                "Italy", 
                "Korea, Republic of", 
                "Russian Federation", 
                "Slovakia", 
                "Spain", 
                "Sweden", 
                "Turkey", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the maximum tolerated dose/recommended phase ll dose (MTD/RP2D) of buparlisib in combination with docetaxel by assessing the incidence of DLTs in Cycle 1; Cycle 1 = 21 days", 
                "measure": "Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1", 
                "safety_issue": "Yes", 
                "time_frame": "Day 21"
            }, 
            {
                "description": "PFS as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. To estimate the treatment effect of docetaxel and buparlisib or placebo on PFS in patients with advanced or metastatic squamous NSCLC.", 
                "measure": "Phase II: Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "After 70 PFS events have been observed at 9 months after patient enrollment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911325"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with at least one adverse event.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after the last dose"
            }, 
            {
                "measure": "Number of patients with laboratory abnormalities.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after the last dose"
            }, 
            {
                "description": "Overall survival (OS) time is measured from the start of study drug to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact. Data will be collected post treatment every 6 weeks until approximately 75% of patients have reached the survival endpoint (Phase I + Phase II)", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Treatment start (phase Ib)/randomization (phase II), every 6 weeks to the date of first document progression for up to 3 years"
            }, 
            {
                "description": "Overall response is the number of participants who had a complete response (CR) or a partial response (PR) based on local investigator's assessment of RECIST 1.1 criteria.", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks from randomization until first documented progression for up to 3 years"
            }, 
            {
                "description": "Time to overall response is defined as the time from the date of first drug intake in Phase Ib and from the date of randomization in Phase II to the date of first documented response.", 
                "measure": "Time to response (ToR)", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks from randomization until first documented progression for up to 3 years"
            }, 
            {
                "description": "Duration of overall response is defined as the elapsed time between the date of first documented response and the following date of event defined as the first documented progression or death due to underlying cancer.", 
                "measure": "Duration of response (DR)", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks from randomization until first documented progression for up to 3 years"
            }, 
            {
                "measure": "Change in electrocardiogram (ECG) and cardiac imaging", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after the last dose"
            }, 
            {
                "measure": "Changes in vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after the last dose"
            }, 
            {
                "description": "cycle = 21 days; end of treatment is defined as 15 days after treatment discontinuation; There is no treatment duration as patients continue to receive drug till toxicity or they withdraw consent", 
                "measure": "Shift in ECOG performance status", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, worst post-baseline result at day 1 of every cycle and at end of study treatment (3 years)"
            }, 
            {
                "measure": "Change in Mood scales", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after the last dose"
            }, 
            {
                "description": "Date of event is defined as at least 10% relative to baseline worsening of the corresponding scale score or death due to any cause", 
                "measure": "Time to definitive 10% deterioration in the global health status/quality of life (QOL) scale score of the EORTC QLQ-C30", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Every 6 weeks until disease progression for up to 3 years"
            }, 
            {
                "description": "Change in the domain scores", 
                "measure": "Change in the global health status/quality of life (QOL) scale score of the EORTC QLQ-C30", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Every 6 weeks until disease progression for up to 3 years"
            }, 
            {
                "measure": "Docetaxel and buparlisib plasma concentrations", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 day 8 and 15, Cycle 2-Cycle n day 1"
            }, 
            {
                "description": "PFS as per RECIST 1.1", 
                "measure": "PFS Phase Ib", 
                "safety_issue": "No", 
                "time_frame": "at 3 months after patient enrollment, every 6 weeks until disease progression for up to 3 years"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}